Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Return on Capital Employed (2022 - 2025)

Axsome Therapeutics' Return on Capital Employed history spans 4 years, with the latest figure at 0.55% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 28.0% year-over-year to 0.55%; the TTM value through Dec 2025 reached 0.55%, up 28.0%, while the annual FY2025 figure was 0.67%, 14.0% up from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.55% at Axsome Therapeutics, up from 0.72% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.39% in Q3 2023 and bottomed at 0.85% in Q3 2024.
  • The 4-year median for Return on Capital Employed is 0.72% (2025), against an average of 0.68%.
  • The largest annual shift saw Return on Capital Employed crashed -46bps in 2024 before it increased 28bps in 2025.
  • A 4-year view of Return on Capital Employed shows it stood at 0.75% in 2022, then surged by 32bps to 0.51% in 2023, then crashed by -65bps to 0.84% in 2024, then skyrocketed by 34bps to 0.55% in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Return on Capital Employed are 0.55% (Q4 2025), 0.72% (Q3 2025), and 0.83% (Q2 2025).